--- title: "Theriva Biologics (TOVX) news: going concern and offering" url: "https://aibio.space/companies/theriva-biologics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TOVX going concern and offering news: Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026. Theriva Biologics, Inc." --- TOVX Theriva Biologics, Inc. AMEX · United States # Theriva Biologics (TOVX) news TOVX going concern and offering news Company Updates · 2026-08-11 ## [Theriva Biologics doses first VIRAGE2 patients and reports cash into Q1 2027](https://aibio.space/news/theriva-biologics-doses-first-virage2-patients-reports-cash-q1-2027/) The NYSE American company reported $11.3 million of cash at June 30, 2026, after first patients were dosed in a Phase 2a trial of more frequent VCN-01 dosing in pancreatic cancer. ## Latest Theriva Biologics news 1. 2026-08-06 Company Updates [Theriva doses first patient in VIRAGE2 pancreatic cancer trial](https://aibio.space/news/theriva-doses-first-patient-virage2-pancreatic-cancer-trial/) The Phase 2a study will test more frequent repeated dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer. 2. 2026-07-07 Company Updates [Theriva receives Spanish authorization for VIRAGE2 trial](https://aibio.space/news/theriva-receives-spanish-authorization-virage2-trial/) Spain's AEMPS cleared the Phase 2a study of more frequent VCN-01 dosing in first-line metastatic pancreatic cancer. 3. 2026-06-11 Company Updates [Theriva reports Phase 1 head and neck cancer results in journal](https://aibio.space/news/theriva-reports-phase-1-head-neck-cancer-results-journal/) Clinical Cancer Research published the Phase 1 study of VCN-01 with durvalumab in patients whose cancer was refractory to immunotherapy. 4. 2026-06-05 Company Updates [Theriva special meeting fails to reach quorum on warrant approval](https://aibio.space/news/theriva-special-meeting-fails-reach-quorum-warrant-approval/) Too few shares were present for the June 5, 2026 special meeting on share issuance for warrants, and the company must call another meeting. 5. 2026-05-05 Company Updates [Theriva reports Q1 2026 results and FDA agreement on Phase 3 design](https://aibio.space/news/theriva-reports-q1-2026-results-fda-agreement-phase-3-design/) The company reported cash of $14.4 million at March 31, 2026, a runway into Q1 2027, and FDA general agreement on a pivotal Phase 3 design for VCN-01. 6. 2026-04-17 Company Updates [Theriva to present VIRAGE trial biomarker data at AACR 2026](https://aibio.space/news/theriva-present-virage-trial-biomarker-data-aacr-2026/) A poster on April 20, 2026 will report tumor response, biomarker and subgroup analyses from the VIRAGE Phase 2b trial of VCN-01. 7. 2026-04-09 Company Updates [Theriva special meeting fails quorum, new meeting to be called](https://aibio.space/news/theriva-special-meeting-fails-quorum-new-meeting-called/) A special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting. 8. 2025-10-02 Distress [Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026](https://aibio.space/news/theriva-biologics-cuts-32-percent-workforce-expects-cash-runway-second/) Theriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024. 9. 2025-06-20 Financings [Theriva Biologics files to sell up to $2,534,352 of stock through at-the-market program](https://aibio.space/news/theriva-biologics-files-sell-up-2-534-352-stock-through-market-program/) Theriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546. ## Theriva Biologics at a glance - **Ticker**: TOVX - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $11.3 million ### Related companies - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX - [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) NASDAQ: OTLK - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Alumis](https://aibio.space/companies/alumis/) NASDAQ: ALMS - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) NASDAQ: SBFM - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) NASDAQ: ARQT - [Akebia Therapeutics](https://aibio.space/companies/akebia-therapeutics/) NASDAQ: AKBA - [Veru](https://aibio.space/companies/veru/) NASDAQ: VERU ### Also on AMEX - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) CLDI - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) EDVA - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) ATNM - [Perspective Therapeutics](https://aibio.space/companies/perspective-therapeutics/) CATX - [Azitra](https://aibio.space/companies/azitra/) AZTR - [Cel-Sci](https://aibio.space/companies/cel-sci/) CVM ## What Theriva Biologics does Theriva Biologics, Inc. describes itself as a diversified clinical-stage company developing therapeutics to treat cancer and related diseases. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus modified for tumor-selective replication and to express the enzyme PH20 hyaluronidase. The company acquired VCN Biosciences, S.L. in March 2022 and moved its strategic focus to oncology. VCN-01 has been evaluated in a Phase 2b study for pancreatic cancer, called VIRAGE, and in a Phase 1 study for retinoblastoma, as well as in other Phase 1 studies for solid tumors including head and neck squamous cell carcinoma. Before the acquisition, the company focused on gastrointestinal diseases with SYN-004 (ribaxamase), designed to degrade certain intravenous beta-lactam antibiotics within the GI tract, and SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase. In February 2026 the company entered into a license agreement with Rasayana Therapeutics, Inc., granting an exclusive worldwide license. | Product or program | What it is | Stage | |---|---|---| | VCN-01 (zabilugene almadenorepvec) | Oncolytic adenovirus for solid tumors that expresses PH20 hyaluronidase | Clinical stage; evaluated in Phase 2b for pancreatic cancer | | SYN-004 (ribaxamase) | Degrades certain IV beta-lactam antibiotics in the GI tract | Clinical development candidate (former GI focus) | | SYN-020 | Recombinant oral formulation of intestinal alkaline phosphatase | Clinical development candidate (former GI focus) | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm). ## Theriva Biologics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$8.6 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/) | [$12.0 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/) | | Cash from operations | [-$16.7 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/) | [-$16.9 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/) | | Cash and equivalents | [$13.1 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/) | [$11.6 million](https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Theriva Biologics Has Theriva Biologics issued a going-concern warning? Our latest story on this, dated Oct 2, 2025: "Theriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/theriva-biologics-cuts-32-percent-workforce-expects-cash-runway-second/). Has Theriva Biologics raised money recently? Our latest story on this, dated Jun 20, 2025: "Theriva Biologics files to sell up to $2,534,352 of stock through at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/theriva-biologics-files-sell-up-2-534-352-stock-through-market-program/). What is the ticker symbol of Theriva Biologics? Theriva Biologics, Inc. trades under the ticker TOVX on AMEX. Where is Theriva Biologics listed? Theriva Biologics, Inc. is listed on AMEX. What is the SEC CIK of Theriva Biologics? The SEC Central Index Key (CIK) for Theriva Biologics, Inc. is 894158. Its filings are on SEC EDGAR. How many shares does Theriva Biologics have outstanding? 45,892,668 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Theriva Biologics listed under? Our directory records Theriva Biologics, Inc. under United States. What does Theriva Biologics do? Our directory classifies Theriva Biologics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Theriva Biologics? The ISIN recorded for Theriva Biologics, Inc. is US87164U5083. Does aibio.space cover Theriva Biologics? aibio.space lists Theriva Biologics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Theriva Biologics incorporated? SEC records list its state or country of incorporation as NV. What does Theriva Biologics develop? Theriva Biologics, Inc. describes itself as a diversified clinical-stage company developing therapeutics to treat cancer and related diseases. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus modified for tumor-selective replication and to express the enzyme PH20 hyaluronidase. What is VCN-01 (zabilugene almadenorepvec) from Theriva Biologics? VCN-01 (zabilugene almadenorepvec): Oncolytic adenovirus for solid tumors that expresses PH20 hyaluronidase Stage: Clinical stage; evaluated in Phase 2b for pancreatic cancer. What is SYN-004 (ribaxamase) from Theriva Biologics? SYN-004 (ribaxamase): Degrades certain IV beta-lactam antibiotics in the GI tract Stage: Clinical development candidate (former GI focus). How much does Theriva Biologics spend on research and development? $8.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Theriva Biologics Members talk about Theriva Biologics (TOVX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Theriva Biologics, newest first. Each line links the filing it comes from. 1. 2026-10-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465926117417/tm2627846d1_def14a.htm) 2. 2026-10-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465926115074/tm2627231d1_pre14a.htm) 3. 2026-08-04 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm) 4. 2026-06-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465926078859/tm2618124d1_def14a.htm) 5. 2026-06-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465926075756/tm2618124d1_pre14a.htm) 6. 2025-10-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465925103770/tm2529686d2_424b5.htm) 7. 2025-10-02 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/tm2527561d1_8k.htm) 8. 2025-06-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465925061182/tm2518361d1_424b5.htm) 9. 2025-05-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465925045934/tm2514445d1_424b5.htm) 10. 2024-12-10 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465924127275/tm2430478d1_s1.htm) 11. 2024-11-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/894158/000110465924113480/tm2427299d1d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:TOVX on TradingView](https://www.tradingview.com/symbols/AMEX-TOVX/). ## SEC filings and registration - **SEC name**: Theriva Biologics, Inc. - **CIK**: 894158 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TOVX (NYSE) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850 - **Phone**: (734) 332-7800 - **Shares outstanding**: 45,892,668 as of 2026-08-07 (10-Q filed 2026-08-11) - **Former names**: Synthetic Biologics, Inc.; ADEONA PHARMACEUTICALS, INC.; PIPEX PHARMACEUTICALS, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/894158/000110465926117417/tm2627846d1_def14a.htm) filed 2026-10-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_8k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926080962/tm2619846d1_8k.htm) filed 2026-07-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/894158/000110465926078859/tm2618124d1_def14a.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/tm2617564d1_8k.htm) filed 2026-06-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000894158), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Theriva Biologics, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker TOVX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Theriva Biologics, Inc. - **Ticker**: TOVX - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US87164U5083 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-TOVX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/theriva-biologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Theriva Biologics (TOVX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/theriva-biologics/